ACL — Australian Clinical Labs Share Price
Last trade - 00:00- AU$505.27m
- AU$806.91m
- AU$697.07m
- 73
- 72
- 33
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.42 | ||
| PEG Ratio (f) | 1.09 | ||
| EPS Growth (f) | 14.08% | ||
| Dividend Yield (f) | 4.26% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.07 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 3.44 | ||
| Price to Sales | 0.75 | ||
| EV to EBITDA | 4.9 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.9% | ||
| Return on Equity | 9.08% | ||
| Operating Margin | 5.78% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 448.45 | 490.57 | 646.7 | 995.6 | 697.07 | 687.16 | 710.45 | 12.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +79.77 | +147.03 | -80.3 | -9.7 | +21.12 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Australian Clinical Labs Limited is a private provider of pathology services. Its laboratories perform a range of pathology tests each year for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients. It performs a range of services for doctors, patients, and corporate clients, including routine pathology tests, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology and cytopathology, hematology, allergy and immunology, serology and microbiology, infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing. Its specialist services include molecular cancer services, obstetrics and gynecology, pharmacogenetic testing, gastroenterology, and hospital services. It has operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory.
Directors
- Michael Alscher NEC (46)
- Melinda Mcgrath CEO
- James Davison CFO
- Eleanor Padman SEC
- Nathanial Thomson NED
- Andrew Dutton NID
- Mark Haberlin NID
- Leanne Rowe NID
- Michael Stanford NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 6th, 2020
- Public Since
- May 14th, 2021
- No. of Shareholders
- 7,351
- No. of Employees
- 5,115
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 200,503,272
- Address
- 1868-1892 Dandenong Road, Clayton, MELBOURNE, 2000
- Web
- Phone
- +61 300453688
- Auditors
- Pitcher Partners
Upcoming Events for ACL
Similar to ACL
Apiam Animal Health
Australian Stock Exchange - SEATS
Artrya
Australian Stock Exchange - SEATS
Cann
Australian Stock Exchange - SEATS
Capitol Health
Australian Stock Exchange - SEATS
Careteq
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:03 UTC, shares in Australian Clinical Labs are trading at AU$2.52. This share price information is delayed by 15 minutes.
Shares in Australian Clinical Labs last closed at AU$2.52 and the price had moved by -29.21% over the past 365 days. In terms of relative price strength the Australian Clinical Labs share price has underperformed the ASX All Ordinaries Index by -34.07% over the past year.
The overall consensus recommendation for Australian Clinical Labs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Australian Clinical Labs dividend yield is 3.97% based on the trailing twelve month period.
Last year, Australian Clinical Labs paid a total dividend of AU$0.10, and it currently has a trailing dividend yield of 3.97%.Looking ahead, the next dividend pay date is 2024-04-26.
We do not have data on when Australian Clinical Labs is to next pay dividends. The historic dividend yield on Australian Clinical Labs shares is currently 3.97%.
To buy shares in Australian Clinical Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$2.52, shares in Australian Clinical Labs had a market capitalisation of AU$505.27m.
Here are the trading details for Australian Clinical Labs:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ACL
Based on an overall assessment of its quality, value and momentum Australian Clinical Labs is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Australian Clinical Labs is AU$3.03. That is 20.16% above the last closing price of AU$2.52.
Analysts covering Australian Clinical Labs currently have a consensus Earnings Per Share (EPS) forecast of AU$0.16 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Australian Clinical Labs. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -18.71%.
As of the last closing price of AU$2.52, shares in Australian Clinical Labs were trading -12.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Australian Clinical Labs PE ratio based on its reported earnings over the past 12 months is 13.42. The shares last closed at AU$2.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Australian Clinical Labs' management team is headed by:
- Michael Alscher - NEC
- Melinda Mcgrath - CEO
- James Davison - CFO
- Eleanor Padman - SEC
- Nathanial Thomson - NED
- Andrew Dutton - NID
- Mark Haberlin - NID
- Leanne Rowe - NID
- Michael Stanford - NID